Veronica P Cipriani1, Sara Klein2. 1. The University of Chicago, 5841 S. Maryland Ave. MC 2030, Chicago, IL, 60637, USA. vcipriani@bsd.uchicago.edu. 2. The University of Chicago, 5841 S. Maryland Ave. MC 2030, Chicago, IL, 60637, USA.
Abstract
PURPOSE OF REVIEW: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that affects nearly 1 million people in the USA and has the potential to profoundly affect physical ability and income potential at a young age. Since a landmark paper was published in 2014, few studies have looked at differences in MS disease characteristics between African-American and Caucasian patients. RECENT FINDINGS: African-American patients often have a more severe MS disease course, as well as biomarker data which can portend a worse prognosis. While the sample sizes are usually quite small, subgroup analyses of African-American patients have been performed to evaluate efficacy of disease-modifying treatments as compared with the entire study population, made up of primarily Caucasians. In an era where we strive for personalized medicine, understanding racial differences in MS may help us better treat African-American patients in the future.
PURPOSE OF REVIEW: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that affects nearly 1 million people in the USA and has the potential to profoundly affect physical ability and income potential at a young age. Since a landmark paper was published in 2014, few studies have looked at differences in MS disease characteristics between African-American and Caucasian patients. RECENT FINDINGS: African-American patients often have a more severe MS disease course, as well as biomarker data which can portend a worse prognosis. While the sample sizes are usually quite small, subgroup analyses of African-American patients have been performed to evaluate efficacy of disease-modifying treatments as compared with the entire study population, made up of primarily Caucasians. In an era where we strive for personalized medicine, understanding racial differences in MS may help us better treat African-American patients in the future.
Authors: I Kister; E Chamot; J H Bacon; P M Niewczyk; R A De Guzman; B Apatoff; P Coyle; A D Goodman; M Gottesman; C Granger; B Jubelt; L Krupp; M Lenihan; F Lublin; C Mihai; A Miller; F E Munschauer; A B Perel; B E Teter; B Weinstock-Guttman; R Zivadinov; J Herbert Journal: Neurology Date: 2010-07-20 Impact factor: 9.910
Authors: Mais Al-Kawaz; Elizabeth Monohan; Eric Morris; Jai S Perumal; Nancy Nealon; Timothy Vartanian; Susan A Gauthier Journal: J Neuroimaging Date: 2016-09-16 Impact factor: 2.486
Authors: Steve Simpson; Wendy Wang; Peter Otahal; Leigh Blizzard; Ingrid A F van der Mei; Bruce V Taylor Journal: J Neurol Neurosurg Psychiatry Date: 2019-06-19 Impact factor: 10.154
Authors: Natalia Gonzalez Caldito; Shiv Saidha; Elias S Sotirchos; Blake E Dewey; Norah J Cowley; Jeffrey Glaister; Kathryn C Fitzgerald; Omar Al-Louzi; James Nguyen; Alissa Rothman; Esther Ogbuokiri; Nicholas Fioravante; Sydney Feldman; Ohemaa Kwakyi; Hunter Risher; Dorlan Kimbrough; Teresa C Frohman; Elliot Frohman; Laura Balcer; Ciprian Crainiceanu; Peter C M Van Zijl; Ellen M Mowry; Daniel S Reich; Jiwon Oh; Dzung L Pham; Jerry Prince; Peter A Calabresi Journal: Brain Date: 2018-11-01 Impact factor: 13.501
Authors: G Comi; M Filippi; F Barkhof; L Durelli; G Edan; O Fernández; H Hartung; P Seeldrayers; P S Sørensen; M Rovaris; V Martinelli; O R Hommes Journal: Lancet Date: 2001-05-19 Impact factor: 79.321
Authors: Annette Langer-Gould; Robyn M Lucas; Anny H Xiang; Jun Wu; Lie H Chen; Edlin Gonzales; Samantha Haraszti; Jessica B Smith; Hong Quach; Lisa F Barcellos Journal: Nutrients Date: 2018-02-07 Impact factor: 5.717
Authors: Annette F Okai; Annette M Howard; Mitzi J Williams; Justine D Brink; Chiayi Chen; Tamela L Stuchiner; Elizabeth Baraban; Grace Jeong; Stanley L Cohan Journal: Neurology Date: 2022-04-25 Impact factor: 11.800